Lymphedema Diagnostics Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Technology (Bioimpedance Analysis, Computed Tomography, Lymphoscintigraphy, Magnetic Resonance Imaging, Near-Infrared Fluorescence Imaging, Ultrasound Imaging, X-Ray Lymphography), By Disease (Cancer, Cardiovascular Disease, Inflammatory Diseases), By End User (Diagnostic Centers, Hospitals, Research & Academic Institutes, Others), By Region and Competition, 2021-2031F

Forecast Period	2027-2031
Market Size (2025)	USD 43.56 Million
CAGR (2026-2031)	7.80%
Fastest Growing Segment	Lymphoscintigraphy
Largest Market	North America
Market Size (2031)	USD 68.35 Million

Market Overview

The Global Lymphedema Diagnostics Market will grow from USD 43.56 Million in 2025 to USD 68.35 Million by 2031 at a 7.80% CAGR. Lymphedema diagnostics comprise medical imaging modalities and screening devices, such as lymphoscintigraphy and bioimpedance spectroscopy, utilized to detect lymphatic dysfunction and quantify fluid volume in patients. The primary drivers supporting market growth include the rising global incidence of secondary lymphedema among cancer survivors and an expanding geriatric population prone to chronic venous insufficiency. These structural factors create a sustained demand for effective detection tools to manage the condition before it progresses. According to the Lymphatic Education & Research Network, in 2024, lymphedema impacts an estimated 10 million Americans and more than 250 million people worldwide. This substantial prevalence underscores the critical necessity for accurate diagnostic solutions to facilitate early intervention and improved patient outcomes.

One significant challenge hindering the broader expansion of the Global Lymphedema Diagnostics Market is the prohibitive cost associated with advanced imaging systems and the lack of adequate insurance coverage in many regions. Limited reimbursement structures for specialized lymphatic testing often discourage healthcare providers from adopting newer technologies and restrict patient access to essential diagnostic procedures. This financial barrier proves particularly detrimental in emerging economies where healthcare budgets are constrained and resource allocation often prioritizes acute care over chronic disease management systems.

Key Market Drivers

The increasing incidence of cancer-associated secondary lymphedema acts as a primary catalyst for the diagnostics market, particularly as survival rates for breast and pelvic cancers improve globally. Healthcare providers are increasingly prioritizing surveillance programs to identify early-stage lymphatic dysfunction in survivors, necessitating the frequent use of diagnostic tools like bioimpedance spectroscopy and lymphoscintigraphy. Since secondary lymphedema is a chronic condition that often develops months or years after treatment, the growing population of cancer survivors creates a sustained demand for longitudinal monitoring. According to the American Cancer Society, January 2024, in the 'Cancer Facts & Figures 2024', approximately 310,720 new cases of invasive breast cancer were expected to be diagnosed in women in the United States alone during the year. This rising patient volume directly correlates with a greater need for accurate detection devices, as these individuals remain at lifelong risk for developing chronic swelling and related complications that require immediate intervention.

Technological innovations in non-invasive diagnostic modalities are further propelling market expansion by enabling more precise and patient-friendly assessments. Manufacturers are integrating digital health platforms with diagnostic devices to streamline data collection, thereby encouraging higher adoption rates among clinics managing lymphedema and related vascular disorders. This modernization is reflected in the financial performance of key industry players who are expanding their portfolios to meet clinical needs. According to Tactile Systems Technology, February 2024, in the 'Fourth Quarter and Fiscal Year 2023 Financial Results', the company reported a total annual revenue of $274.4 million, driven by the robust demand for their lymphedema management and diagnostic solutions. Furthermore, the global burden of cancer continues to necessitate scalable diagnostic infrastructure to handle future caseloads. According to the International Agency for Research on Cancer, in 2024, the agency predicted a widespread surge in oncology needs, estimating over 35 million new cancer cases annually by 2050, which reinforces the long-term requirement for robust lymphedema diagnostic capabilities.

Download Free Sample Report

Key Market Challenges

The prohibitive cost associated with advanced imaging systems and the lack of adequate insurance coverage constitute a primary restraint on the expansion of the Global Lymphedema Diagnostics Market. Healthcare facilities often hesitate to procure expensive capital equipment, such as lymphoscintigraphy units or bioimpedance spectroscopy devices, due to the uncertainty of reimbursement and low return on investment. In many jurisdictions, payers classify specialized lymphatic imaging as non-essential or investigational, resulting in denied claims and restricted clinical adoption. This lack of financial support forces medical providers to rely on subjective physical examinations rather than precise instrumental diagnostics, thereby stalling the revenue growth of device manufacturers.

Furthermore, the substantial financial liability placed on patients creates a significant barrier to accessing these diagnostic procedures. According to the American Association of Plastic Surgeons, in 2025, the average cost for conservative lymphedema management was $14,648 per patient, with average out-of-pocket expenses reaching $9,765. This high level of personal financial burden discourages patients from pursuing comprehensive diagnostic evaluations and compels healthcare systems to prioritize acute care spending over chronic management tools. Consequently, the market faces reduced demand for sophisticated screening technologies as the economic ecosystem remains unfavorable for both providers and patients.

Key Market Trends

The Proliferation of Handheld and Portable Point-of-Care Devices is fundamentally reshaping the diagnostic landscape by decentralizing limb volume measurement. Clinicians are increasingly abandoning bulky, expensive perometers in favor of mobile application-based 3D imaging solutions that offer clinical-grade accuracy on standard smartphones. This technological democratization addresses the critical need for accessible screening in non-specialized and resource-limited settings, allowing for earlier intervention without heavy capital investment. According to Docwire News, March 2025, in the 'App Successfully Detects Lymphedema in Breast Cancer Patients' article, a recent validation of the LymphaTech 3D Imaging System demonstrated intraclass correlation coefficients of ≥0.99 when compared to traditional perometer methods, confirming its reliability for widespread clinical utility.

Simultaneously, the Expansion of Digital Health Platforms for Remote Patient Monitoring is fostering a more integrated and connected care environment for chronic management. Industry leaders are pivoting towards next-generation connected devices that seamlessly combine therapeutic delivery with digital data tracking, thereby enhancing patient compliance and enabling longitudinal surveillance of disease progression. This strategic integration is driving robust commercial adoption as healthcare providers prioritize ecosystems that streamline patient data. According to Tactile Systems Technology, November 2025, in the 'Q3 2025 Earnings Call Transcript', the company reported that lymphedema product revenue increased 11% year-over-year to $72.4 million, significantly driven by the market introduction and uptake of their connected Nimbl platform.

Segmental Insights

Within the Global Lymphedema Diagnostics Market, the lymphoscintigraphy segment is recognized as the fastest-growing category due to its critical role in confirming definitive diagnoses. This imaging technique is favored because it offers a functional assessment of the lymphatic system, allowing clinicians to visualize fluid movement and identify blockages with high precision. The International Society of Lymphology acknowledges this method as a primary tool for evaluating the condition when clinical assessment is insufficient. Consequently, the increasing adoption of surgical interventions, which require the detailed anatomical mapping provided by lymphoscintigraphy, is driving the accelerated expansion of this market segment.

Regional Insights

North America maintains a dominant position in the global lymphedema diagnostics market due to a high prevalence of secondary lymphedema associated with cancer treatments. This regional leadership is supported by well-developed healthcare infrastructure and favorable reimbursement frameworks provided by the Centers for Medicare & Medicaid Services, which improve patient accessibility to testing. Additionally, the strong presence of major medical device manufacturers and active advocacy from organizations like the National Lymphedema Network drive clinical awareness. These factors collectively ensure the continuous expansion of the diagnostic sector across the region.

Recent Developments

• In May 2025, ImpediMed presented new results from the PREVENT trial at the American Society of Breast Surgeons (ASBrS) Annual Meeting, highlighting the critical importance of pre-treatment baseline screening for breast cancer-related lymphedema. The study data demonstrated that without a pre-treatment baseline measurement using bioimpedance spectroscopy (BIS), a significant majority of patients with early signs of the condition would be missed, potentially delaying effective intervention. These findings reinforced the clinical necessity of establishing objective baseline fluid and body composition measurements before cancer treatment begins to improve detection rates and patient outcomes.
• In October 2024, Stryker’s fluorescence imaging technology received a significant validation following the announcement of FDA approval for the use of Indocyanine Green (ICG) dye in lymphatic mapping during breast cancer surgery. The approval was supported by results from the FILM B clinical study, sponsored by the company, which showed that the fluorescence imaging technique offered accurate visualization of lymphatic channels, enabling surgeons to avoid injury or perform lymphovenous anastomosis. This development marked a major advancement in the intraoperative assessment and prevention of lymphedema for patients undergoing breast cancer procedures.
• In October 2024, ImpediMed announced that the National Accreditation Program for Breast Centers (NAPBC), a quality program of the American College of Surgeons, updated its accreditation standards to include lymphedema prevention programs utilizing bioimpedance spectroscopy (BIS). The 2024 standards formally recognized BIS as an evidence-based guideline for the clinical assessment and management of lymphedema, marking a significant market milestone for the technology. This update mandated that accredited centers implement objective measurement protocols, further establishing the company’s digital health platform as a standard of care for survivorship programs.
• In March 2024, Canon Medical Systems Europe unveiled the Aplio me, a new ultrasound system designed for high-throughput environments, at the European Congress of Radiology (ECR) in Vienna. The system features advanced imaging capabilities, including Superb Micro-vascular Imaging (SMI), which supports the detailed visualization of low-velocity blood flow and lymphatic channels essential for lymphedema diagnosis. This product launch expanded the company's portfolio with a device that integrates AI-powered workflow tools to enhance diagnostic precision and efficiency in clinical settings, including specialized lymphedema clinics.

Key Market Players

• ImpediMed
• BioCompression Systems
• Mego Afek
• Stryker
• Philips Healthcare
• GE HealthCare
• Siemens Healthineers
• Canon Medical
• Perimed
• Fluoptics

By Technology	By Disease	By End User	By Region
Bioimpedance Analysis Computed Tomography Lymphoscintigraphy Magnetic Resonance Imaging Near-Infrared Fluorescence Imaging Ultrasound Imaging X-Ray Lymphography	Cancer Cardiovascular Disease Inflammatory Diseases	Diagnostic Centers Hospitals Research & Academic Institutes Others	North America Europe Asia Pacific South America Middle East & Africa

Report Scope:

In this report, the Global Lymphedema Diagnostics Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

• Lymphedema Diagnostics Market, By Technology:

• Bioimpedance Analysis
• Computed Tomography
• Lymphoscintigraphy
• Magnetic Resonance Imaging
• Near-Infrared Fluorescence Imaging
• Ultrasound Imaging
• X-Ray Lymphography

• Lymphedema Diagnostics Market, By Disease:

• Cancer
• Cardiovascular Disease
• Inflammatory Diseases

• Lymphedema Diagnostics Market, By End User:

• Diagnostic Centers
• Hospitals
• Research & Academic Institutes
• Others

• Lymphedema Diagnostics Market, By Region:

• North America
• United States
• Canada
• Mexico
• Europe
• France
• United Kingdom
• Italy
• Germany
• Spain
• Asia Pacific
• China
• India
• Japan
• Australia
• South Korea
• South America
• Brazil
• Argentina
• Colombia
• Middle East & Africa
• South Africa
• Saudi Arabia
• UAE